INDIANAPOLIS, Feb. 19, 2016 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a public biotechnology company advancing a new class of oral biologic drugs for addressing the gut microbiome and new approaches to discovering drugs for the treatment of hepatitis B virus (HBV) infection, today announced that senior management will give a corporate presentation and update at two upcoming investor conferences:
- The RBC Capital Markets 2016 Global Healthcare Conference in New York, NY on Wednesday, February 24, 2016 at 2:35pm ET.
- Cowen and Company's 36th Annual Healthcare Conference in Boston, MA on Monday, March 7, 2016 at 4:00pm ET.
The presentations will be webcast live and may be accessed through a link on the Investor Relations page of the company's website at assemblybio.com. Archived versions of the webcasts will be available on the Assembly website for 90 days beginning several hours after the live presentations.
For more information about the RBC Capital Markets 2016 Global Healthcare Conference, click here. For more information about the Cowen and Co. 36th Annual Healthcare Conference, click here.
About Assembly Biosciences
Assembly Biosciences, Inc. is a public biotechnology company advancing a new class of oral biologic drugs for addressing the gut microbiome and novel approaches to discovering drugs for the treatment of hepatitis B virus (HBV) infection. Assembly’s team has significant experience in infectious disease drug discovery and development and has collectively helped bring more than 10 anti-infective products to the market. The company’s HBV-Cure Program is aimed at increasing cure rates and is advancing multiple drug candidates that address upstream and downstream viral targets in the HBV lifecycle for possible use in combination therapy. The company’s Microbiome Program consists of a fully integrated platform that includes a robust strain identification and selection process, methods for strain isolation and growth under cGMP conditions, and a patent pending delivery system, GEMICELTM, which allows for targeted oral delivery of live biologic and conventional therapies to the lower GI tract. The lead program from this platform, AB-M101, is in development for the treatment of C. difficile infection. For more information, visit assemblybio.com.